Join our Pharma goal ( Pharma jobs) Facebook group click on below
About Mylan:-
Mylan is the American Global Generic and Specialty Pharmaceutical Company, registered with the Netherlands, with headquarters in Mainfield, Hertfordshire, the UK's main operating offices and world headquarters in Canansburgh, Pennsylvania. In 2007, Mylan took interest in the generic business business of generic drugs for the largest pharmaceutical ingredient (API), India-based Matrix Laboratories Limited, and Germany-based Merck KGA. By these acquisitions, Mylan became the world's third largest generic and pharmaceutical company in the world's second largest generic and specialty pharmaceuticals company.
Mylan became public on February 1, 73, in OTC Market. It is listed on the NASDAQ, and its shares are a component of NASDAQ Biotechnology, NASDAQ 100, and S & P 500 index.
Develop and develop a company for a wide range of medical topics including oncology, anaphylaxis, antiretroviral, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious diseases, gastroenterology, diabetology / endocrinology and women's healthcare.
In 2016, the price of the EpinePen of Mylan, the Epinephrine AutoExpector, became controversial and widely known as "price gauging". As a result, Mylan discovered whether Epipal was mistakenly classified under a common form of Medicare drug rabat program, Pharmaceutical Fraud. In October 2016, Mylan agreed to give $ 465 million to the investigation and access to the Corporate Integration Agreement with the concession program by the United States Department of Justice. In a report published on June 12, 2017, the company's shareholder services criticized Mylan's "outspaid compensation" for Mylan's directors. Former CEO Robert Kori received $ 98 million 2016 pay packages if losses were caused by a shareholder loss and company filled with Epine debate. Mylan's shareholders requested the removal of Mylan's current directors.
History:-
Founded in the 1980s
In 1961, Milan Puscor and Don Panjoe founded Mylan Pharmaceuticals as a drug distributor. In 1966, Mylan started producing penicillin G tablets as well as vitamins and other dietary supplements.
In 1969, Ponce left Mylan and in 1973 Pushkar left the company and faced financial difficulties. As the board's chairman, Roy McCainat appointed the board, in 1976, Pushkar promised to come back.
In the 1980s, Mylan ceased working as the Contract Manufacturing Organization and instead sold under the "Mylan label" brand of their products.
In the 1980s
Mylen and other generic generic companies acquired value in the second half of the Hatch-Waxman Act in 1984; In the second half of the law, Mylan's earnings went up by 166% to $ 12.5 million in eighteen months and its stock value increased by 800%.
Diazide and MaxZide
In the 1980s, Dyazedes, one of the world's most consumed medicines, was a dwarfic that was a mixture of trimaterin and hydrochlorothiazide. Since 1965, it had come into the market and its patent had expired in the 1980s.The introduction of generic versions caused clichés, because the preparation of dyazids became convertible batch which was impossible for generic producers to show their versions being bioavailability.
Some ordinary companies cheated by trying to bring a common version of dihydride. In 1987, Bolar Pharmaceutical had approved the first generic version, but it was found that Bolar had deployed Diazide for his own version to conduct studies submitted to the FDA. Until 1998, the FDA withdrew its clearance on its suspicious basis and filed criminal charges against Bolar, whose sentence was finally convicted in 1991.
Mylan has chosen to develop a new version of trymetrin / hydrochlorothiazheed combination drugs instead of going in the normal way; They developed in a different, more stable form and used different doses compared to each active ingredient (50 mg hydrochlorothiazide and 75 mg trimaterine) 25 mg of diazide, hydrochlorothiazide and 50 mg triamterine. The drugs against generic drugs were approved as a new drug. Their products were named MaxZaide and they were approved in 1984. Once allowed to take one dose once daily, Mylan and his marketing partner Leaderley believe that they will help in competing against dyeing, which was sold at $ 210 in 1983.However, Mylan's drugs were declared illegal in patents and its marketing specificity expired in 1987, so that the general competition.
Mylan was also concerned about its competitors and companies that brought FDA generic and generic versions of Maxx. Mylan appointed private investigators to examine the competitiveness of his opponents and when he found evidence of corruption, he submitted to the House Overseat and Investigation Committee, which explored and in the Generic Drugs Department of the Food and Drug Administration and other common companies.In order to approve the market of generic versions of phosphoric, phosphoric and phosphoric pharmaceuticals, two companies were given initial attention to Mylan's initial scrutiny and Mylan's Maxxide was used to obtain bioequalvance data, which helped both companies to withdraw its general competitors. Mylan's product.
The corruption in the newborn generic industry and the FDA office's office corruption was massively protected and this caused widespread concern among doctors and the public in the late 1980s and early 1990s. Generic medicines are not exactly the same. Branded medicines they have to change.
The acquisition begins
In 1987, Mylan was ready to enter Bolar's joint venture to buy Somerset Pharmaceuticals; Mylan wanted to get a new drug in Somersets' drug detection capacity, as well as Parkinson's, Siliglin; The contract was completed in 1988, but its reliance was dependent on the CDGline's FDA approval in 1989.
In the 1990s
Mylan bought Berttech Inc. for transdermal patch technology in 1993 and he was named as Assistant. Mylan, Mylan Technologies Inc., in 1999 (MTI) changed the name of the company MTI finally came as a contract manufacturer for the Selignline Transdermal Patches and was the first company to make generic nitroglycerin, estradiol, Clonidine and Fentanal transdermal patches market.
In 1996, Mylan bought the UDL Laboratories, which supplied generic generic medicines for institutional and long-term maintenance facilities.
In 1998, when she was the world's largest generic company, Lorazapam tripled after Mylan increased the prices of its products from the Federal Trade Commission. Mylan is an Italian company professor with a medication
